Table 1.
Primary role | Gene | Protein | Function | Cellular processes | References |
---|---|---|---|---|---|
Redox homeostasis | GCLC | Glutamate–cysteine ligase catalytic subunit | Catalytic subunit of the enzyme responsible for the rate-limiting step in synthesis of the cellular antioxidant glutathione | Maintenance of cellular redox homeostasis | [36, 37, 40, 41] |
Redox homeostasis | GLCM | Glutamate–cysteine ligase modifier subunit | Modifier subunit of the enzyme responsible for the rate-limiting step in synthesis of the cellular antioxidant glutathione | Maintenance of cellular redox homeostasis | [36–38, 40, 123] |
Redox homeostasis | GPX2 | Glutathione peroxidase 2 | Detoxification of H2O2 and an important cellular antioxidant | Maintenance of cellular redox homeostasis | [126, 127] |
Redox homeostasis | PRDX1 | Peroxiredoxin 1 | Reduces peroxides, regulates cellular concentrations of H2O2 | Maintenance of cellular redox homeostasis | [36–38, 41, 117] |
Redox homeostasis | SRXN1 | Sulfiredoxin | Contributes to the thioredoxin-based antioxidant system that reduces oxidized protein thiols; reduces sulfinic acid in proteins | Thiol maintenance, maintenance of cellular redox homeostasis | [36, 37, 40, 41] |
Redox homeostasis | TXN1 | Thioredoxin 1 | Reversible oxidation of active center allows participation in dithiol–disulfide exchange reactions; reduces sulfenic acid in proteins | Thiol maintenance, maintenance of cellular redox homeostasis | [36, 37, 39–41, 117] |
Detoxification | ABCB6 | ATP-binding cassette B6 (MDR/TAP) | Mitochondrial transporter; transports heme and porphyrin in an ATP-dependent manner, crucial for heme metabolism | Phase III drug metabolism, heme metabolism | [37, 41] |
Detoxification | ABCC2 | ATP-binding cassette C2 (MRP2) | Biliary transport/hepatic excretion; involved in the extrusion of certain anti-cancer drugs and implicated in multidrug resistance | Phase III drug metabolism | [36, 38, 39, 41, 120] |
Detoxification | AKR1B10 | Aldo-keto reductase 1B10 | Converts retinal to retinol; reduces aromatic and aliphatic aldehydes | Phase I drug metabolism and retinal metabolism | [36, 38–40] |
Detoxification | AKR1C1 | Aldo-keto reductase 1C1 | Converts 4-hydroxy-2-nonenal to 1,2-dihydroxy nonene; inactivates progesterone | Phase I drug metabolism | [36, 39, 40, 128] |
Detoxification | AKR1C3 | Aldo-keto reductase 1C3 | Type 5 17β-hydroxysteroid dehydrogenase and prostaglandin F2α synthase | Phase I drug metabolism | [129–131] |
Detoxification | CES1G | Carboxyl esterase 1G | Catalyzes the trans-esterification of xenobiotics, hydrolysis of long-chain fatty acid esters | Phase I drug metabolism, fatty acid oxidation, fatty acid degradation | [123] |
Detoxification | CES1H | Carboxyl esterase 1H | Catalyzes the trans-esterification of xenobiotics, hydrolysis of long-chain fatty acid esters | Phase I drug metabolism, fatty acid oxidation, fatty acid degradation | [123] |
Detoxification | GSTA1 | Glutathione S-transferase A1 | Detoxification and metabolism of electrophilic compounds; metabolism of bilirubin and certain anti-cancer drugs; also displays glutathione peroxidase activity | Phase II drug metabolism, cytoprotection | [38, 41, 58] |
Detoxification | GSTM1 | Glutathione S-transferase M1 | Detoxification and metabolism of electrophilic compounds | Phase II drug metabolism | [38, 41, 58] |
Detoxification | NQO1 | NAD(P)H quinone oxidoreductase 1 | Reduces quinones to hydroquinones and prevents the one-electron reduction of quinones that would otherwise produce free radicals | Phase I drug metabolism | [36, 37, 40] |
Heme metabolism | FECH | Ferrochelatase | Catalyzes the insertion of Fe2+ into protoporphyrin IX during heme synthesis; localized in mitochondria | Heme metabolism | [37, 40] |
Heme metabolism | HMOX1 | Heme oxygenase 1 | Cleaves heme to produce biliverdin during heme catabolism | Heme metabolism | [36–41] |
Lipid metabolism | AWAT1 | Acyl-CoA wax alcohol acyltransferase 1 | Catalyzes the production of wax esters from long-chain alcohols and acyl-CoA-derived fatty acids; enriched in skin | Lipid metabolism | [123] |
Lipid metabolism | FABP1 ↓ | Fatty acid binding protein 1 | Binds long-chain fatty acids, their CoA derivatives, and bile acids in the cytoplasm for intracellular transport | Lipid uptake and intracellular transport | [116] |
Lipid metabolism | LIPH | Lipase H | Membrane-bound triglyceride lipase that hydrolyzes phosphatidic acid to produce 2-acyl lysophosphatidic acid, which is a potent bioactive lipid mediator | Platelet aggregation, smooth muscle contraction, cell proliferation and motility | [123] |
Lipid metabolism | PPARγ | Peroxisome proliferator-activated receptor γ | Transcription factor that orchestrates lipid metabolism; key regulator of adipocyte differentiation and glucose homeostasis | Lipid mobilization, β-oxidation of fatty acids, adipocyte differentiation, glucose metabolism | [37, 116] |
Lipolysis | ACOT7 | Acyl-CoA thioesterase 7 | Catalyzes the hydrolysis of palmitoyl-CoA and other long-chain fatty acids to form free fatty acid and CoA | Fatty acid oxidation, fatty acid degradation | [115] |
Lipolysis | ACOX2 | Acyl-CoA oxidase 2 | Catalyzes peroxisomal degradation of long branched-chain fatty acids and bile acid intermediates | Fatty acid oxidation, fatty acid degradation | [123] |
Lipogenesis | ACLY ↓ | ATP citrate lyase | Catalyzes the production of acetyl-CoA and oxaloacetate from CoA and citrate using ATP | Lipogenesis, cholesterol synthesis, gluconeogenesis | [115, 116, 118] |
Lipogenesis | FASN ↓ | Fatty acid synthase | Generation of long-chain fatty acids such as palmitate from malonyl-CoA and acetyl-CoA using NADPH | Lipogenesis | [115, 116, 118] |
Lipogenesis | SCD1 ↓ | Stearoyl-CoA desaturase 1 | Catalyzes the introduction of a double bond into stearoyl-CoA to create the mono-unsaturated fatty acid oleic acid | Lipogenesis | [115, 122] |
Lipogenesis | SREBF1 ↓ | Sterol-regulatory element binding transcription factor 1 | Transcription factor that controls expression of the LDL receptor, and genes involved in glucose metabolism and lipid synthesis | Lipogenesis, glucose metabolism | [116] |
Glucose metabolism | FGF21 ↓ | Fibroblast growth factor 21 | Stimulates glucose uptake in adipocytes, involved in regulation of insulin | Glucose uptake and clearance, insulin signaling | [132] |
Cholesterol synthesis | HMGCS1 ↓ | 3-Hydroxy-3-methylglutaryl-CoA synthase 1 | Catalyzes the condensation of acetyl-CoA and acetoacetyl-CoA to produce HMG-CoA, the substrate for HMG-CoA reductase | Cholesterol synthesis | [115, 116] |
NADPH generation | G6PD | Glucose-6-phosphate dehydrogenase | Generates NADPH in the pentose phosphate pathway; maintains cellular glutathione redox status | Pentose phosphate pathway, NADPH generation, maintenance of cellular redox homeostasis | [36, 38–41, 115] |
NADPH generation | IDH1 | Isocitrate dehydrogenase 1 | Catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate, using NADP+ as a cofactor, outside the context of the citric acid cycle in the cytoplasm or in peroxisomes | NADPH generation | [38, 41, 115] |
Pentose synthesis | TALDO1 | Transaldolase 1 | Involved in production of ribose 5′-phosphate required for nucleic acid synthesis | Pentose phosphate pathway | [36, 37, 39, 115] |
Pentose synthesis | TKT | Transketolase | Channels excess sugars from the pentose phosphate pathway to glycolysis by the creation of glyceraldehyde 3-phosphate | Pentose phosphate pathway, glycolysis | [36] |
Scavenger receptor | CD36 | CD36 molecule/fatty acid translocase | Major platelet glycoprotein that binds long-chain fatty acids and functions in the transport and regulation of transport of fatty acids | Fatty acid transport, adhesion | [133] |
Autophagy | p62/SQSTM1 | Sequestosome 1 | Required for formation and autophagic degradation of polyubiquitin-containing bodies; used as a scaffold protein | Autophagy, inflammation | [134] |
Tissue regeneration | NOTCH1 | Notch 1 | Transmembrane protein containing multiple epidermal growth factor-like repeats that is involved in signaling processes during development and tissue regeneration | Cell fate determination, developmental signaling | [135] |
Regulation of xenobiotic response | AHR | Aryl hydrocarbon receptor | Transcription factor that binds planar aromatic compounds and upregulates genes involved in xenobiotic metabolism, including CYP family members | Xenobiotic metabolism | [124] |
E3 ligase substrate adaptor | Keap1 | Kelch-like ECH associated protein 1 | E3 ubiquitin ligase substrate adaptor that targets proteins for degradation by the 26S proteasome; known negative regulator of Nrf2 | Targeting for ubiquitination, Nrf2 repression, regulation of antioxidant response | [37] |
Heterodimeric binding partner | MAFG | Musculoaponeurotic fibrosarcoma G | Transcriptional regulator; forms heterodimers with a number of transcription factors, including Nrf2, allowing their activation; also forms homodimers restricting the activation of obligate heterodimeric partner molecules | Transcriptional activation, regulation of anti-oxidant response | [37, 40, 41, 123] |
Regulation of antioxidant response | NFE2L2 | NF-E2 p45-like 2 | Transcription factor that regulates genes involved in the oxidative stress response; maintains cellular redox homeostasis and detoxification and contributes to lipid and carbohydrate metabolism | Drug metabolism, xenobiotic metabolism, maintenance of cellular redox homeostasis | [119] |
Regulation of lipid metabolism | PPARα ↓ | Peroxisome proliferator-activated receptor α | Transcription factor, key regulator of lipid metabolism; activator of Nrf2 | Lipid mobilization, fatty acid oxidation, lipogenesis, gluconeogenesis, ketogenesis | [116, 125] |
Transcriptional regulator | RXRα | Retinoid X receptor α | Transcriptional regulator; mediates the biological effect of retinoids by forming homo- or heterodimers and binds to target gene sequences; known negative regulator of Nrf2; known binding partner and activator of PPARα | Transcriptional activation, Nrf2 repression, regulation of antioxidant response, PPARα activation | [37, 41] |
A selection of Nrf2-target genes taken from the literature is shown. Genes that are in bold (with an adjacent down arrow) are those that have been reported to be downregulated by Nrf2.